TrialCard Selects Infinitus Systems To Automate Payer Contact Center Activity apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
TrialCard s Policy Reporter Announces Launch Of Its Coverage Viewer Pharmacy Edition
New offering combines best-in-class pharmacy covered lives with the market s largest payer policy repository
News provided by
Share this article
MORRISVILLE, N.C., Feb. 16, 2021 /PRNewswire/ Policy Reporter today announced the launch of its
Coverage Viewer Pharmacy Edition, becoming the first and only provider in the marketplace to offer detailed policy coverage criteria layered with both pharmacy and medical covered lives data. As a result, life science companies can now receive the most accurate, real-time data to inform brand access and health plan contracting decisions.
Pharmaceutical and medical policies are complex, unstructured documents that can be challenging to capture and navigate. Policy Reporter, acquired by TrialCard in 2019, expertly automates the necessary, but often frustrating, act of staying abreast of policy and formulary information across the payer landscape. Historica
Share this article
Share this article
MORRISVILLE, N.C., Jan. 14, 2021 /PRNewswire/ TrialCard Incorporated announced today it again achieved double-digit year-over-year revenue growth in 2020, despite the challenges presented by the COVID-19 pandemic. This growth comes after the biopharmaceutical solutions provider posted consecutive years of 44% YOY organic growth in both 2018 and 2019. 2020 was a difficult year for everyone on many different levels, said TrialCard President and CEO Mark Bouck. Despite the COVID-19-related hurdles we faced, the implementation of our multi-level business continuity plan was 100% complete by the end of the first quarter. This quick response set the tone for the rest of the year, and we were honored to be chosen to provide marketing support services for a well-known COVID-19 therapy. Throughout 2020, our team stayed remarkably focused on the tasks at hand and delivered for our biopharmaceutical clients and their patients.